Skip to main content

Patient Search

Testimonials Testimonials

Displaying 1 - 7 of 7

Nashville Biosciences Blood Sample Collection Study

Multiple Cancer Types

Colon, Liver, Lung, Non Small Cell, Ovarian, Pancreatic, Rectal
N/A
Bernard, Gordon
VICCMD18123

A Quality Improvement Initiative to Prevent Venous Thromboembolism (VTE) Among Gynecologic Oncology Patients Undergoing Chemotherapy

Multiple Cancer Types

Cervical, Gynecologic, Ovarian
N/A
Brown, Alaina
VICCGYN19119

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Multiple Cancer Types

ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody. The safety, tolerability, PK, and biological activity of ATRC-101 will be characterized when administered every two weeks (Q2W) or every 3 weeks (Q3W) as a monotherapy or in combination with other anticancer agents.
Breast, Colon, Lung, Melanoma, Non Small Cell, Ovarian, Phase I, Rectal
I
Berlin, Jordan
NCT04244552
VICCPHI2040

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Multiple Cancer Types

This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SEA-TGT works to treat solid tumors and lymphomas. The study will have three parts. Part A of the study will find out how much SEA-TGT should be given to patients. Part B will use the dose found in Part A to find out how safe SEA-TGT is and if it works to treat solid tumors and lymphomas. Part C will study how well SEA-TGT with sasanlimab works to treat solid tumors.
Gastric/Gastroesophageal, Head/Neck, Lung, Non Small Cell, Ovarian, Phase I
I
Crispens, Marta
NCT04254107
VICCPHI2125

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Ovarian

This trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for women with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.
Ovarian
N/A
Brown, Alaina
NCT04251052
NRGGYNCC008

A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

Multiple Cancer Types

This clinical trial will evaluate DS-6000a in participants with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC). The main goals of this study will be to investigate the recommended dose of DS-6000a that can be given safely to participants, assess the side effects of DS-6000a, and evaluate the effectiveness of DS-6000a.
Kidney (Renal Cell), Ovarian, Phase I
I
Rini, Brian
NCT04707248
VICCPHI2115

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors

Multiple Cancer Types

This phase III trial studies how well active surveillance, bleomycin, etoposide, carboplatin or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating germ cell tumors.
Germ Cell (Pediatrics), Gynecologic, Ovarian
III
Borinstein, Scott
NCT03067181
COGAGCT1531